$ABVX

Abivax SA (ABVX) shares fell 44% to a worst-ever day after late-stage ulcerative colitis trial results for obefazimod showed ~51% clinical remission at week 44 vs 10.4% on placebo, but reports of non-melanoma skin cancers and other malignancies in older patients raised safety concerns. Jefferies cut its target to $90 from $160 and downgraded to Hold; Wedbush raised to Neutral with $90 target. Martin Shkreli said GLP-1 fears later proved unfounded.

EQS-News: ABIVAX / Key word(s): Regulatory Admission Abivax Announces Positive Pre-NDA Interaction with the FDA for Obefazimod 30.07.2026 / 22:05 CET/CEST The issuer is solely responsible for the content of this announcement.

Apple shares sink on disappointing September quarter sales outlook PARIS - Abivax SA (Euronext Paris:ABVX / NASDAQ:ABVX) announced today the completion of its pre-New Drug Application interaction with the U.S. Food and Drug Administration for obefazimod, a treatment for moderately to severely active ulcerative colitis in adults.

Jefferies downgraded Abivax to ‘Hold’ from ‘Buy’ and slashed the price target to $90 from $160, a 30% potential downside from the stock’s closing price on Monday. Abivax said its late-stage trial to treat ulcerative colitis showed strong results. However, there was a small number of reported skin cancer cases and other malignancies in the higher-dose group.

Abivax SA (ABVX) said it expanded its commercial leadership team with four appointments covering marketing, patient services, sales and commercial operations, and market access/pricing. The company is preparing for potential U.S. commercialization of obefazimod (ABX464), with an NDA planned for Q4 2026, according to the press release.

BioPharma Dive roundup covers AstraZeneca’s eplontersen failure in a major heart disease study, boosting expectations for rival TTR amyloidosis drugs from Alnylam and BridgeBio. Other items include ARPA-H funding, GSK ending a neuroscience alliance with Alector, Vera Therapeutics’ FDA nod for IgA nephropathy, and Vertex’s $10B plan to buy Crinetics.

Abivax SA (ABVX) said it closed its previously announced underwritten public offering of 7.36M American Depositary Shares, including the underwriters’ option. Gross proceeds were about $920.0M (€807.4M) and estimated net proceeds about $874.1M (€767.1M). The company expects funding to support operations into Q4 2029.

Abivax shares rose nearly 6% in Paris after underwriters fully exercised a greenshoe option to buy 960,000 additional ADSs, raising total gross proceeds from its upsized public offering to $920m (€807m). The ADS offering priced at $125 on July 1. Jefferies upgraded Abivax to Buy, PT $158; company says cash runway extends into Q2 2029.

Abivax said underwriters fully exercised an option to buy additional ADSs, raising gross proceeds from a recent offering to $920 million (7.36M ADSs), versus $800 million initially. Net proceeds were $874.1 million. The company plans to use funds for potential U.S. commercialization of obefazimod and ongoing trials; it expects funding through Q2 2029. Shares rose in premarket.

Abivax SA said underwriters fully exercised their option to buy 960,000 additional ADSs (15% of initial ADSs) in its U.S. offering of 6.4M ADSs. The company expects delivery with a July 6, 2026 closing. Total ADSs: 7.36M; gross proceeds about $920.0M (€807.4M) and estimated net about $874.1M (€767.1M). Proceeds will fund obefazimod commercialization plans, R&D (ulcerative colitis/Crohn’s), and general purposes.